Kurse werden geladen...
Prognose
| Kaufen | 1 |
| Halten | 0 |
| Verkaufen | 0 |
Scoring-Modelle
| Dividenden-Strategie | 0 / 15 |
| HGI-Strategie | 3 / 18 |
| Levermann-Strategie | -6 / 13 |
News
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting
Reqorsa® Immunogene Therapy is a Potential Therapy for Ras Inhibitor Resistant Non-Small Cell Lung Cancer AUSTIN, Texas , March 26, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators will present at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025 in Chicago, Illinois. The collaborators will present positive preclinical data from a study of its lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), for the treatment of KRASG12C mutant non-small cell lung cancer (NSCLC).» Mehr auf prnewswire.com
Genprex Collaborators Selected to Present Positive Preclinical Data on Diabetes Gene Therapy at the 2025 American Diabetes Association 85th Scientific Sessions
Novel Gene Therapy Program is Addressing Type 1 and Type 2 Diabetes AUSTIN, Texas , March 25, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that its research collaborators have been selected to present at the upcoming 2025 American Diabetes Association (ADA) 85th Scientific Session being held June 20-23, 2025 in Chicago, Illinois. The collaborators will present positive preclinical data and research from studies of GPX-002, the Company's diabetes gene therapy drug candidate.» Mehr auf prnewswire.com
Genprex to Participate at BIO Europe Spring 2025
AUSTIN, Texas , March 4, 2025 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that members from its executive leadership team will be attending and participating at BIO Europe Spring taking place March 17-19, 2025 in Milan, Italy. In attendance will be Ryan Confer, President and Chief Executive Officer and Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing.» Mehr auf prnewswire.com
Unternehmenszahlen
| (EUR) | Dez. 2024 | |
|---|---|---|
| Umsatz | 0,00 | 100,00% |
| Bruttoeinkommen | 0,00 | 100,00% |
| Nettoeinkommen | −4,16 Mio | 22,41% |
| EBITDA | −4,17 Mio | 23,03% |
Fundamentaldaten
| Metrik | Wert |
|---|---|
Marktkapitalisierung | 5,03 Mio€ |
Anzahl Aktien | 24,15 Mio |
52 Wochen-Hoch/Tief | 3,55€ - 0,19€ |
| Dividenden | Nein |
Beta | -0,39 |
KGV (PE Ratio) | −0,05 |
KGWV (PEG Ratio) | 0,00 |
KBV (PB Ratio) | 0,59 |
KUV (PS Ratio) | 0,00 |
Unternehmensprofil
Genprex, Inc. ist ein Gentherapie-Unternehmen in der klinischen Phase und konzentriert sich auf die Entwicklung von Therapien für Patienten mit Krebs und Diabetes. Sein führender Produktkandidat ist REQORSA (GPX-001) zur Behandlung von nicht-kleinzelligem Lungenkrebs und kleinzelligem Lungenkrebs. Das Unternehmen entwickelt außerdem GPX-002, eine Gentherapie für Diabetes im präklinischen Stadium. Genprex, Inc. wurde im Jahr 2009 gegründet und hat seinen Hauptsitz in Austin, Texas.
| Name | GENPREX INC DL-,001 |
| CEO | Ryan M. Confer M.S. |
| Sitz | Austin, tx USA |
| Website | |
| Industrie | Biowissenschaften: Hilfsmittel und Dienstleistungen |
| Börsengang | |
| Mitarbeiter | 15 |
Ticker Symbole
| Börse | Symbol |
|---|---|
NASDAQ | GNPX |
Frankfurt | 2DE.F |
London | 0A8I.L |
München | 2DE.MU |
Assets entdecken
Shareholder von GENPREX INC DL-,001 investieren auch in folgende Assets
